← Back to Clinical Trials
Recruiting NCT05851534

NCT05851534 Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05851534
Status Recruiting
Phase
Sponsor Maastricht University Medical Center
Condition Prehabilitation
Study Type INTERVENTIONAL
Enrollment 2,575 participants
Start Date 2024-09-02
Primary Completion 2027-09-02

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Preoperative optimisation program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,575 participants in total. It began in 2024-09-02 with a primary completion date of 2027-09-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and intervention of 8 potentially (partly) modifiable risk factors in patients with (suspected) pancreatic cancer will improve outcome. The main questions it will aim to answer are: 1. Does a prehabilitation program improve the time to functional recovery after pancreatic surgery? 2. Does a prehabilitation program lead to a reduction in the Comprehensive Complication Index after pancreatic surgery?

Eligibility Criteria

Inclusion Criteria: * All patients who are planned for a curative treatment with or without neoadjuvant treatment and elective pancreatic resection in one of the centres of the Dutch Pancreatic Cancer Group (i.e. all centres performing major pancreatic surgery) Exclusion Criteria: * age \< 18 years * acute pancreatic resections (resection scheduled within two weeks)

Contact & Investigator

Central Contact

Marcel den Dulk, MD PhD

✉ marcel.den.dulk@mumc.nl

📞 +3143 3875492

Principal Investigator

Marcel den Dulk, MD PhD

PRINCIPAL INVESTIGATOR

Maastricht University Medical Center/ University Maastricht

Frequently Asked Questions

Who can join the NCT05851534 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Prehabilitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05851534 currently recruiting?

Yes, NCT05851534 is actively recruiting participants. Contact the research team at marcel.den.dulk@mumc.nl for enrollment information.

Where is the NCT05851534 trial being conducted?

This trial is being conducted at 's-Hertogenbosch, Netherlands, Amsterdam, Netherlands, Amsterdam, Netherlands, Breda, Netherlands and 9 additional locations.

Who is sponsoring the NCT05851534 clinical trial?

NCT05851534 is sponsored by Maastricht University Medical Center. The principal investigator is Marcel den Dulk, MD PhD at Maastricht University Medical Center/ University Maastricht. The trial plans to enroll 2,575 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology